Search research articles
Contact Us
Filters
Showing results (501-510 of 962) with videos related to
Page
of 97
Sort By:
Circulation. Cardiovascular Interventions
|
January 1, 2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention
Neal N Sawlani, Robert A Harrington, Gregg W Stone, et al.
Circulation. Arrhythmia and Electrophysiology
|
January 27, 2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
An H Bui, Christopher P Cannon, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology
|
January 10, 2015
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials
Gregg W Stone, Roxana Mehran, Patrick Goldstein, et al.
European Heart Journal
|
May 23, 2014
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
Uwe Zeymer, Arnoud van 't Hof, Jennifer Adgey, et al.
Vascular Pharmacology
|
January 31, 2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes
William A E Parker, Dominick J Angiolillo, Fabiana Rollini, et al.
Journal of the American Heart Association
|
February 19, 2025
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial
Rahul Aggarwal, Deepak L Bhatt, Ph Gabriel Steg, et al.
American Heart Journal
|
May 27, 2026
Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease
Ph Gabriel Steg, Shaun G Goodman, J Wouter Jukema, et al.
Circulation. Cardiovascular Interventions
|
March 16, 2019
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y<sub>12</sub> Inhibitor Pretreatment
Jeremie Abtan, Gregory Ducrocq, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology
|
July 15, 2026
Aspirin Withdrawal in Patients With Coronary Artery Disease
Mattia Galli, Davide Capodanno, Jurrien Ten Berg, et al.
Journal of the American Heart Association
|
August 27, 2020
HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome
Franck Boccara, Murielle Mary-Krause, Valérie Potard, et al.
Page
of 97
Search research articles
Search
Showing results (501-510 of 962) with videos related to
Sort By:
Page
of 97
Circulation. Cardiovascular Interventions
|
January 1, 2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention
Neal N Sawlani, Robert A Harrington, Gregg W Stone, et al.
Circulation. Arrhythmia and Electrophysiology
|
January 27, 2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
An H Bui, Christopher P Cannon, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology
|
January 10, 2015
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials
Gregg W Stone, Roxana Mehran, Patrick Goldstein, et al.
European Heart Journal
|
May 23, 2014
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
Uwe Zeymer, Arnoud van 't Hof, Jennifer Adgey, et al.
Vascular Pharmacology
|
January 31, 2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes
William A E Parker, Dominick J Angiolillo, Fabiana Rollini, et al.
Journal of the American Heart Association
|
February 19, 2025
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial
Rahul Aggarwal, Deepak L Bhatt, Ph Gabriel Steg, et al.
American Heart Journal
|
May 27, 2026
Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease
Ph Gabriel Steg, Shaun G Goodman, J Wouter Jukema, et al.
Circulation. Cardiovascular Interventions
|
March 16, 2019
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y<sub>12</sub> Inhibitor Pretreatment
Jeremie Abtan, Gregory Ducrocq, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology
|
July 15, 2026
Aspirin Withdrawal in Patients With Coronary Artery Disease
Mattia Galli, Davide Capodanno, Jurrien Ten Berg, et al.
Journal of the American Heart Association
|
August 27, 2020
HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome
Franck Boccara, Murielle Mary-Krause, Valérie Potard, et al.
Page
of 97